Core Points - Catheter Precision, Inc. has executed a 1-for-19 reverse stock split effective August 15, 2025, with trading continuing under the symbol "VTAK" on a split-adjusted basis [1][2] - The reverse stock split will reduce the number of issued shares from approximately 23,316,520 to about 1,657,640 shares [4] - Stockholders will not receive fractional shares; instead, they will receive a pro rata portion of the net proceeds from the sale of fractional shares [3] Company Details - The reverse stock split will not change the par value per share and will affect all stockholders uniformly [2][3] - Stockholders holding shares in brokerage accounts should direct inquiries to their brokers, while all stockholders of record can contact the Company's transfer agent for assistance [4] - Additional information regarding the reverse stock split is available in the Company's definitive proxy statement filed with the SEC [5]

Core Viewpoint - Vaxart, Inc. is seeking stockholder support for a reverse stock split proposal, which has been endorsed by leading proxy advisory firms ISS and Glass Lewis [1][3]. Group 1: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [5]. - The company's vaccines are designed to be administered in pill form, eliminating the need for refrigeration and reducing the risk of needle-stick injuries [5]. - Current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [5]. Group 2: Stockholder Engagement - The senior management team will host a virtual stockholder fireside chat on August 20, 2025, to address stockholder questions, particularly regarding the reverse stock split and Nasdaq compliance [2]. - Stockholders of record as of July 29, 2025, are encouraged to vote on the proposal by September 4, 2025 [4]. Group 3: Communication and Support - Investors can submit questions in advance of the conference call via email or through the webcast portal [3]. - A replay of the webcast will be available on the company's website after the event [3].

Core Viewpoint - Salarius Pharmaceuticals, Inc. will implement a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum closing bid price requirement of $1.00 [2][4]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 5:00 p.m. Eastern Time on August 15, 2025, with trading on a split-adjusted basis starting August 18, 2025 [1]. - The number of shares outstanding will decrease from approximately 7.6 million to about 509,000 shares [4]. - All outstanding options and warrants will be adjusted accordingly, and stockholders will receive cash for any fractional shares based on the closing price on August 15, 2025 [4][5]. Group 2: Approval Process - Stockholders approved the reverse stock split proposal at a special meeting on July 8, 2025, allowing the Board of Directors to determine the split ratio [3]. - The specific 1-for-15 ratio was subsequently approved by the Board of Directors [3]. Group 3: Company Overview - Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies, with two drug candidates: seclidemstat and SP-3164 [7]. - Seclidemstat is being studied in a Phase 1/2 clinical trial for hematologic cancers, while SP-3164 is an oral small molecule protein degrader [7].

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $8.3 million, compared to $7.1 million in Q1 2025 and $8.5 million in Q2 2024, indicating a sequential increase driven by product shipments in the home and enterprise market [26] - Non-GAAP gross profit margin for Q2 2025 was 46%, down from 49.9% in Q1 2025 and 51% in Q2 2024, reflecting a unique product mix [26] - Non-GAAP operating expenses decreased to $9.7 million in Q2 2025 from $10.4 million in Q1 2025 and $12.8 million in Q2 2024, showing effective cost reduction measures [27] - The net loss for Q2 2025 was $5.3 million, or a loss of $1 per share, compared to a net loss of $6.5 million in Q1 2025 and $7.7 million in Q2 2024 [28] - Cash and cash equivalents at the end of Q2 2025 were $14.3 million, down from $18.5 million at the end of Q1 2025 [28] Business Line Data and Key Metrics Changes - Home and enterprise revenue was approximately $7.1 million in Q2 2025, while mobile revenue was approximately $1.2 million [26] - The mobile business saw a similar revenue profile to the prior quarter, with shipments supporting residual demand from previously launched smartphone models [14] - Revenue from the home and enterprise market increased over 20% sequentially, driven by a combination of seasonal demand recovery and ramping shipments of new SOCs [18] Market Data and Key Metrics Changes - The TrueCut Motion platform has been credited with three new theatrical releases, indicating growing acceptance and demand in the market [10] - Titles utilizing TrueCut Motion have achieved over $4 billion at the box office, demonstrating the format's value to studio partners [12] - The mobile market is expected to remain flat, with Chinese OEMs focusing on differentiation to expand globally [33] Company Strategy and Development Direction - The company is focusing on two defined approaches in the mobile segment: expanding the target market with a low-cost mobile graphics accelerator and pursuing premium gaming experiences [15] - The strategic review process for the Pixelworks Shanghai subsidiary is nearing closure, with potential new ownership structures being evaluated [23] - The company aims to reach profitability for its Shanghai subsidiary by Q4 2025, despite delays in mobile revenue recovery [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of the TrueCut Motion format, anticipating it to become a standard for premium large format cinemas [12] - The company is better positioned to drive bottom-line results from a small uplift in revenue due to previous cost structure reductions [22] - Management noted that the overall market for projectors is expected to remain similar to 2024, with no significant impacts from global trade dynamics observed so far [18] Other Important Information - The company received approximately $1.6 million in cash subsidies as part of China's Little Giant program, aiding in R&D expenses [27] - The company completed all scheduled end-of-life shipments of transcoding products in Q4 2024, with potential one-time orders from prior customers being evaluated [19] Q&A Session Summary Question: Why are mobile customers in China emphasizing custom ASIC? - Management indicated that differentiation is key for Chinese OEMs in a flat market, as they seek to expand globally and compete against established brands [33][38] Question: Will the transcoding one-time customer revenue hit in Q3 or Q4? - Management confirmed that the revenue from the transcoding order would be recognized in Q4 [42] Question: How will Pixelworks be different post-transaction regarding the Shanghai division? - Management stated it is too early to provide details on the strategic direction post-transaction [44] Question: How broad is the ASIC design and IP application? - Management clarified that the IP is not limited to smartphones and can be applied in tablets, AR/VR markets, and other display technologies [48] Question: What is driving the strength in the home and enterprise market? - Management noted that the strength is partly due to a higher ASP of new SOCs and stocking needs from customers [52]

Core Viewpoint - Veru Inc. is implementing a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00, which was approved by shareholders on July 25, 2025 [3]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 11:59 pm CT on August 8, 2025, with trading on a split-adjusted basis starting on August 11, 2025 [1]. - All outstanding stock options and equity incentive plans will be proportionally affected, with every 10 shares converting into 1 share without changing the par value of $0.01 per share [2]. - No fractional shares will be issued; shareholders will receive cash payments for any fractional shares [2]. Group 2: Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on innovative medicines for cardiometabolic and inflammatory diseases [6]. - The company's drug development includes enobosarm, a selective androgen receptor modulator aimed at improving body composition, and sabizabulin, a microtubule disruptor for treating inflammation in cardiovascular disease [6].

Core Viewpoint - Lucid may be preparing to lower its annual production guidance ahead of its second-quarter earnings call, with a Neutral rating and a price target of $3, indicating a potential upside of approximately 24% from its current price of $2.42 [1] Production and Delivery Performance - Production and delivery volumes for Q2 fell short of expectations, with Lucid delivering 3,309 vehicles, missing Cantor's estimate of 3,791 and the Visible Alpha consensus of 3,611 [2] - A key focus will be on gross margins as Lucid aims to improve its persistently high negative gross margins [2] Future Product Launches - Cantor expects management to provide more details on the initial sales of the Gravity SUV, which began deliveries earlier this year, and to confirm the schedule for the launch of its high-volume midsize SUV, a crucial element of Lucid's turnaround strategy [3] Strategic Partnerships and Financial Moves - In July, Lucid announced a $300 million partnership with Uber to develop a next-generation premium global robotaxi program, with plans for Uber to deploy at least 20,000 Lucid vehicles equipped with Nuro's autonomous driving system over the next six years [4] - Lucid has requested shareholder approval for a 1-for-10 reverse stock split, highlighting the pressure on the company as it faces challenges with profitability and scaling in a competitive EV market [4]

Core Viewpoint - Vivid Seats Inc. is implementing a $25 million cost reduction program to enhance long-term efficiency and adapt to current market challenges, while maintaining a positive outlook on the live events industry as a long-term opportunity [2][3]. Financial Performance - For Q2 2025, Vivid Seats reported a Marketplace Gross Order Value (GOV) of $685.5 million, a decrease of 31% from $998.1 million in Q2 2024 [6]. - Revenues for Q2 2025 were $143.6 million, down 28% from $198.3 million in Q2 2024 [6]. - The company experienced a net loss of $263.3 million in Q2 2025, compared to a net loss of $1.2 million in Q2 2024 [6]. - Adjusted EBITDA for Q2 2025 was $14.4 million, down from $44.2 million in Q2 2024 [6]. Operational Metrics - Marketplace orders totaled 2,173 in Q2 2025, down from 3,097 in Q2 2024 [5]. - Resale orders were 97 in Q2 2025, slightly down from 101 in Q2 2024 [5]. - The company faced 47,845 event cancellations in Q2 2025, compared to 52,392 in Q2 2024 [8]. Cost Reduction Strategy - The $25 million cost reduction program aims to right-size the organization and improve efficiency, with full implementation expected by the end of 2025 [2][3]. - A portion of the savings will be reinvested to stabilize revenue streams as the company looks towards 2026 and beyond [3]. Market Outlook - Despite current pressures on consumer spending and competitive intensity, the company views the live events sector as a durable long-term opportunity [2]. - The company anticipates positive cash flow in Q3 2025, driven by seasonal improvements and a belief that June's industry volume softness was atypical [3]. Stock Activity - A 1-for-20 reverse stock split of Class A and Class B common stock was approved, effective August 6, 2025, to enhance stock performance [10]. Company Overview - Vivid Seats, founded in 2001, is a leading online ticket marketplace focused on connecting fans with live events, offering a wide selection of tickets and a rewards program [12].

Core Viewpoint - MacKenzie Realty Capital, Inc. has announced a 1-for-10 reverse stock split to increase its common stock price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 5:01 p.m. Eastern Standard Time on August 4, 2025, with trading on a split-adjusted basis starting August 5, 2025 [1]. - The split will convert ten existing shares into one new share, reducing the number of outstanding shares from approximately 16,760,978 to about 1,676,098 [2]. - Stockholders entitled to fractional shares will receive cash equivalent to the fractional amount multiplied by the closing price on August 1, 2025 [2]. Group 2: Administrative Aspects - Computershare, Inc. will serve as the exchange agent for the reverse stock split, and stockholders will not need to take action to receive their post-split shares [3]. - The CUSIP number for the company will change to 55453W501 effective at the time of the split [4]. Group 3: Company Overview - MacKenzie Realty Capital, Inc. is a West Coast-focused REIT, aiming to invest at least 80% of its total assets in real property, with a portfolio consisting of approximately 50% multifamily and 50% boutique class A office properties [5]. - The company has maintained a dividend payout every year since its inception and currently holds interests in 4 multifamily properties and 8 office properties, along with 2 multifamily developments [5].

The struggling real estate tech specialist is considering a reverse stock split. Investors eagerly shut the door on real estate transaction platform developer Opendoor Technologies (OPEN -7.87%) on Monday. They didn't take kindly to news of an important vote on the company's future, and sent the share price down by almost 8% on the day. Meanwhile, the S&P 500 (^GSPC 0.02%) flatlined across the session, indicating that many other stocks would have been better pickups. Decision delayed In its words, "an appro ...

Core Viewpoint - Opendoor Technologies Inc. has announced the adjournment of its Special Meeting of Stockholders to August 27, 2025, to allow more time to assess market conditions and the company's stock price [1][5]. Proposal and Compliance - The Special Meeting was originally convened to consider two proposals regarding a discretionary reverse stock split of the company's common stock, which would only be pursued if deemed beneficial by the Board of Directors [2]. - The company received a notice from Nasdaq in May indicating non-compliance with listing rules due to its stock price being below $1.00 per share for 30 consecutive business days [3]. - To regain compliance, Opendoor's stock price must be at least $1.00 per share for a minimum of 10 consecutive business days by November 24, 2025 [4]. Meeting Details - The adjourned Special Meeting will continue to be held online, and stockholders are encouraged to vote during the adjournment period [6][7]. - The record date for stockholders entitled to vote remains June 4, 2025 [7].